Hsbc Holdings PLC Vaxcyte, Inc. Transaction History
Hsbc Holdings PLC
- $176 Billion
- Q3 2025
A detailed history of Hsbc Holdings PLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 50,625 shares of PCVX stock, worth $2.46 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,625
Previous 19,216
163.45%
Holding current value
$2.46 Million
Previous $624,000
192.15%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PCVX
# of Institutions
316Shares Held
132MCall Options Held
493KPut Options Held
162K-
Janus Henderson Group PLC London, X013.1MShares$638 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$600 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$583 Million7.4% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$484 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.32MShares$405 Million0.18% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.89B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...